PACIRA BIOSCIENCES, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
PACIRA BIOSCIENCES, INC. (PCRX) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2018-02-28
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-09-30 was 6.00K shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 0.00 shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2016 was 0.00 shares, a 100.00% decline from fiscal 2015.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2015 was 6.00K shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2014 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2017-12-31 | 0.00 shares 10-K · filed 2018-02-28 | |||
| 2016-12-31 | 0.00 shares 10-K · filed 2018-02-28 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-02 | 0.00 shares 10-Q · filed 2016-11-02 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-04 | 0.00 shares 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-02 | |||
| 2015-12-31 | 6.00K shares 10-K · filed 2018-02-28 | |||
| 2015-09-30 | 6.00K shares 10-Q · filed 2016-11-02 | 6.00K shares 10-Q · filed 2016-11-02 | ||
| 2015-06-30 | 6.00K shares 10-Q · filed 2016-08-04 | 6.00K shares 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | 6.00K shares 10-Q · filed 2016-05-02 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-03-01 | 0.00 shares 10-K · filed 2016-02-25 | ||
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-10-27 | 0.00 shares 10-Q · filed 2015-10-27 | ||
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-07-30 | 0.00 shares 10-Q · filed 2015-07-30 | ||
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-04-30 | |||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |